Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Spotlight

GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines

Business

Deals
Earnings
Manufacturing

Policy & Regulation

Regulatory Landscape
Drug Pricing
IP & Litigation

Tools & Trackers

What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings

Conference Coverage

Partner Insights

Generics Bulletin Perspectives

Exploring market-shifting topics for the off-patent sector.

Medtech Insight

Generics Bulletin

BALANCE Model Delay May Lead To Revisions, Higher Near-Term Medicare Costs

Apr 22 2026

• By Cathy Kelly

CMS backing off 2027 launch of obesity drug payment demonstration in Part D. — CMS backing off 2027 launch of obesity drug payment demonstration in Part D. (Shutterstock)

Related Content

BALANCE GLP-1 Model: CMS Offering Part D Plans ‘Strong’ Participation Incentives

Jan 08 2026

Off-BALANCE? Obesity Drug Model May Need Nearly Universal Part D Plan Participation

Mar 10 2026

Novo, Lilly Lower GLP-1 Prices, ‘Enabling’ Medicare, Medicaid Coverage In Obesity

Nov 07 2025

FDA Says Lilly’s Foundayo Approved In Record Time

Apr 01 2026

Weight Loss Drug Coverage Will Not Pay For Itself, US CBO Affirms

Oct 22 2024

Related Companies

Novo Nordisk A/S

Eli Lilly and Company

More from Generics Bulletin

More from Medicare

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
Editorial Standards
Award-Winning Journalism
Help
AdvertiseOpens in new window
Contact Us
Evaluate Home

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Generics Top 50 Ranking
Biosimilars
Generics
Value Added Medicines

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window